
Opinion|Videos|June 2, 2025
Considerations for Ruxolitinib Therapy in Steroid-Refractory cGVHD
Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).
Advertisement
Episodes in this series

Steroid Tapering with Second-Line Therapy
This detailed segment covers approaches to steroid tapering when initiating second-line therapy. The panelists agree on:
- Waiting 3-4 weeks after starting a new agent (like ruxolitinib) before beginning steroid taper
- Prioritizing steroid discontinuation before tapering other agents
- Tapering steroids by approximately 10mg every 4 weeks, slowing the taper at lower doses
- Very gradual tapering of ruxolitinib once steroids are discontinued, sometimes using alternate-day dosing
Dr Lee notes that at Fred Hutchinson Cancer Center, they taper ruxolitinib more slowly than the prescribing information recommends, sometimes tapering to 5 mg several days per week before complete discontinuation.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article

The FDA granted FTD to opantistomig, a PD-L1/4-1BB bispecific antibody, for first-line treatment of biliary tract cancer.

Texas Oncology’s virtual care navigation pilot supported 740 patients on oral oncolytics across 11 community sites, offering a scalable model for at-home care.

For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.

During a live event, Seth M. Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor.

A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.

RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
As New TGCT Therapies Advance, Route, Duration, and Coverage Shape CSF1R Inhibitor Choice
4
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
5


